Refine by
Glaucoma Progression Equipment & Supplies
6 equipment items found
Manufactured by:Reichert, Inc based inDepew, NEW YORK (USA)
Ocular Response Analyzer® (ORA) G3 is the only device that measures Corneal Hysteresis (CH) and Corneal Compensated IOP (IOPcc). Corneal Hysteresis has consistently shown to be a more powerful predictor of, and strongly associated with, glaucoma progression, more so than key risk factors such as IOP and CCT. IOPcc is a pressure measurement that is less ...
Manufactured by:Haag-Streit Diagnostics based inBern, SWITZERLAND
The Octopus 600 covers all your essential perimetry needs in an easy-to-use device: central field static testing, rapid screening, a easy-to-read analysis software and the ability to network it with integrated EyeSuite ...
Manufactured by:Kowa American Corporation based inTorrance, CALIFORNIA (USA)
Kowa's extensive normative database considers both the central field and the periphery thus ensuring consistent, accurate assessments when using a Kowa AP-7000 perimeter. Full threshold modes offer macular, central, and peripheral coverage up to 80°, while screening modes provide swift evaluation of the visual field. To shorten test times, quick modes are available for both threshold and ...
Manufactured by:Haag-Streit Diagnostics based inBern, SWITZERLAND
Everything you need; The Octopus 900 performs standard white-on-white threshold testing in just 2–4 minutes in the central visual field. With its comprehensive test library for central and peripheral tests and its flexible printouts both in Octopus and HFA-format it covers all your clinical ...
Manufactured by:Oculus Optikgeräte GmbH based inWetzlar, GERMANY
The revolutionary Corvis ST records the reaction of the cornea to a defined air pulse with a newly developed high-speed Scheimpflug-camera that takes over 4 300 images per second. IOP and corneal thickness can be measured with great precision on the basis of the Scheimpflug ...
Manufactured by:NeuroScientific Biopharmaceuticals Ltd. based inCottesloe, AUSTRALIA
Multiple indications with unmet medical need. “Our company goal is to create new products that reach their target in the brain and act as a protector against nerve cells injury. Currently, there are no approved drugs that can slow down or halt neurodegeneration. We believe that EmtinB has potential to bridge this gap and bring this breakthrough medicine to clinics, bringing new hope to ...